Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Derbel, Olfa ^a   Wang, Qing ^a   Desseigne, Françoise ^a   Rivoire, Michel ^a   Meeus, Pierre ^a   Peyrat, Patrice ^a   Stella, Mattia ^a   Martel Lafay, Isabelle ^a   Lemaistre, Anne Isabelle ^a   De La Fouchardière, Christelle ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAF GENE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; KRAS GENE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PI3KCA GENE; RECTUM CARCINOMA; RECTUM SURGERY; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION RATE; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTORS;

EID: 84876711354     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-200     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342. 10.1056/NEJMoa032691, 15175435.
3. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004, 239(6):818-825. 10.1097/01.sla.0000128305.90650.71, 1356290, 15166961.
4. Adam R, Wicherts DA, de Haas RJ, Ciacio O, Levi F, Paule B, Ducreux M, Azoulay D, Bismuth H, Castaing D. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. J Clin Oncol 2009, 27(11):1829-1835. 10.1200/JCO.2008.19.9273, 19273699.
5. Van CE, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29(15):2011-2019. 10.1200/JCO.2010.33.5091, 21502544.
6. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27(19):3109-3116. 10.1200/JCO.2008.20.6771, 19451431.
7. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986, 1(8496):1479-1482.
8. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345(9):638-646. 10.1056/NEJMoa010580, 11547717.
9. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355(11):1114-1123. 10.1056/NEJMoa060829, 16971718.
10. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006, 93(10):1215-1223. 10.1002/bjs.5506, 16983741.
11. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24(28):4620-4625. 10.1200/JCO.2006.06.7629, 17008704.
12. Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg 1990, 211(2):187-195. 10.1097/00000658-199002000-00011, 1357963, 2405793.
13. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351(17):1731-1740. 10.1056/NEJMoa040694, 15496622.
14. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial. J Clin Oncol 2011, 29(20):2773-2780. 10.1200/JCO.2010.34.4911, 21606427.
15. Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, Francois E, de La RG, Bouche O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahe MA, Becouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010, 28(10):1638-1644. 10.1200/JCO.2009.25.8376, 20194850.
16. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004, 22(10):1785-1796. 10.1200/JCO.2004.08.173, 15067027.
17. de Campos-Lobato LF, Stocchi L, da Luz MA, Kalady MF, Geisler D, Dietz D, Lavery IC, Remzi FH, Fazio VW. Downstaging without complete pathologic response after neoadjuvant treatment improves cancer outcomes for cIII but not cII rectal cancers. Ann Surg Oncol 2010, 17(7):1758-1766. 10.1245/s10434-010-0924-4, 20131015.
18. Schubbert S, Bollag G, Lyubynska N, Nguyen H, Kratz CP, Zenker M, Niemeyer CM, Molven A, Shannon K. Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol 2007, 27(22):7765-7770. 10.1128/MCB.00965-07, 2169154, 17875937.
19. Lievre A, Laurent-Puig P. Genetics: Predictive value of KRAS mutations in chemoresistant CRC. Nat Rev Clin Oncol 2009, 6(6):306-307. 10.1038/nrclinonc.2009.69, 19483733.
20. Lievre A, Bachet JB, Le CD, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66(8):3992-3995. 10.1158/0008-5472.CAN-06-0191, 16618717.
21. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011, 22(7):1535-1546. 10.1093/annonc/mdq632, 21228335.
22. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC, Giovannucci EL, Fuchs CS. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009, 27(9):1477-1484. 10.1200/JCO.2008.18.6544, 2659340,2659340, 19237633.
23. Kato S, Iida S, Higuchi T, Ishikawa T, Takagi Y, Yasuno M, Enomoto M, Uetake H, Sugihara K. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 2007, 121(8):1771-1778. 10.1002/ijc.22890, 17590872.
24. He Y, Van't Veer LJ, Mikolajewska-Hanclich I, van Velthuysen ML, Zeestraten EC, Nagtegaal ID, van de Velde CJ, Marijnen CA. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res 2009, 15(22):6956-6962. 10.1158/1078-0432.CCR-09-1165, 19903786.
25. Dresen RC, Peters EE, Rutten HJ, Nieuwenhuijzen GA, Demeyere TB, van den Brule AJ, Kessels AG, Beets-Tan RG, van Krieken JH, Nagtegaal ID. Local recurrence in rectal cancer can be predicted by histopathological factors. Eur J Surg Oncol 2009, 35(10):1071-1077. 10.1016/j.ejso.2009.03.007, 19364631.
26. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999, 18(3):813-822. 10.1038/sj.onc.1202367, 9989833.
27. Bengala C, Bettelli S, Bertolini F, Sartori G, Fontana A, Malavasi N, Depenni R, Zironi S, Del GC, Luppi G, Conte PF. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Br J Cancer 2010, 103(7):1019-1024. 10.1038/sj.bjc.6605853, 2965865, 20842128.
28. Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, Soderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004, 25(4):527-533. 10.1093/carcin/bgh049, 14688025.
29. Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, Wolff HA, Herrmann MK, Beissbarth T, Becker H, Ried T, Ghadimi M. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010, 94(1):76-81. 10.1016/j.radonc.2009.10.001, 19913317.
30. Di NF, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De DS, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26(35):5705-5712. 10.1200/JCO.2008.18.0786, 19001320.
31. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lievre A, Cortet M, Bouvier AM, Rat P, Roignot P, Faivre J, Laurent-Puig P, Piard F. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008, 122(10):2255-2259. 10.1002/ijc.23388, 18224685.
32. He Y, Van't Veer LJ, Lopez-Yurda M, van de Velde CJ, Marijnen CA. Do rectal cancer patients with PIK3CA mutations benefit from preoperative radiotherapy with regard to local recurrences?. Clin Cancer Res 2010, 16(24):6179. 10.1158/1078-0432.CCR-10-1437, 21169263.
33. Michelassi F, Vannucci LE, Montag A, Chappell R, Rodgers J, Block GE. Ras oncogene expression as a prognostic indicator in rectal adenocarcinoma. J Surg Res 1988, 45(1):15-20. 10.1016/0022-4804(88)90015-7, 3392989.
34. Grana TM, Rusyn EV, Zhou H, Sartor CI, Cox AD. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res 2002, 62(14):4142-4150.
35. Bengala C, Bettelli S, Bertolini F, Salvi S, Chiara S, Sonaglio C, Losi L, Bigiani N, Sartori G, Dealis C, Malavasi N, D'Amico R, Luppi G, Gatteschi B, Maiorana A, Conte PF. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 2009, 20(3):469-474.
36. Zauber NP, Marotta SP, Berman E, Grann A, Rao M, Komati N, Ribiero K, Bishop DT. Molecular genetic changes associated with colorectal carcinogenesis are not prognostic for tumor regression following preoperative chemoradiation of rectal carcinoma. Int J Radiat Oncol Biol Phys 2009, 74(2):472-476. 10.1016/j.ijrobp.2008.08.020, 19304403.
37. Davies JM, Trembath D, Deal AM, Funkhouser WK, Calvo BF, Finnegan T, Weck KE, Tepper JE, O'Neil BH. Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. Radiat Oncol 2011, 6:114. 10.1186/1748-717X-6-114, 3180690, 21910869.